Stock Market Impact: Biohaven Ltd. (NYSE:BHVN) shares rose 8.5% on Wednesday after the company disclosed positive preliminary Phase 1b results for two experimental autoimmune‑disease drugs.
Listed Companies and Sectors: The announcement concerns Biohaven Ltd., a biotechnology/pharmaceutical firm; the information is material for the Pharma / Healthcare sector.
Investment Flows: The article does not mention any foreign direct investment, foreign portfolio investment, or other capital‑flow implications.
Interest Rates, Inflation, and Liquidity: No references to monetary policy, interest‑rate changes, inflation trends, or liquidity measures are provided.
Fiscal or Monetary Policy: No fiscal‑policy or central‑bank actions are discussed in the release.
